An ongoing dialogue on HIV/AIDS, infectious diseases,
March 1st, 2009
Sedation for Colonoscopies in HIV Patients: Debate Rages
Here’s a problem we’re grappling with:
A patient with HIV needs a colonoscopy, but is on either a ritonavir-boosted protease inhibitor or an efavirenz-based regimen.
(This must be something like 90% of HIV patients as of March 1, 2009, based on my extremely unscientific gut impression.)
For efavirenz, midazolam is contraindicated; for ritonavir, same story — or “consider therapy modification”, according to one source I found. Ditto fentanyl.
So what should be given for sedation? (Important side note: if you told me pre-1996 that this would be a critical management question for my HIV patients, I would have thought you were out of your mind.)
Lots of different views here in Boston, including:
- Give the usual meds, titrate to effect
- NEVER give midazolam with either efavirenz or ritonavir; instead, use lorazepam, etc
- Stop HIV meds 1 day in advance, then give midazolam and fentanyl
Does anyone know? Or does anyone have sufficient experience to share?
Categories: Antiretroviral Rounds, HIV, Patient Care
Tags: colonoscopy, fentanyl, HIV, hiv patients, lorazepam, midazolam, protease, protease inhibitor, titrate
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
4 Responses to “Sedation for Colonoscopies in HIV Patients: Debate Rages”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
Sorry. No data so far.
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026 August 6, 2026Bundibugyo virus, a filovirus, is currently spreading in the Democratic Republic of Congo. This report presents early data on symptoms and illness severity as well as diagnostic challenges.
- Ebola at 50 — Lessons for Outbreak Response and Preparedness August 6, 2026An accurate history of Ebola begins with partnerships, including those between responders and the populations they serve. One of its key lessons is that equity must be integral to outbreak preparedness.
- Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines August 6, 2026The Bundibugyo virus outbreak in the DRC and Uganda has focused concern on potential countermeasures. Investigators assessed cross-reactive immune responses in serum obtained during previous Ebola vaccine trials.
- The Inequality–Pandemic Cycle — Rethinking Preparedness August 6, 2026Increasing pandemic frequency and increasing economic inequality are creating a self-reinforcing cycle. What’s needed is therefore a new, inequality-informed approach to pandemic preparedness.
- The Social Contract of Bundibugyo Ebola Isolation August 6, 2026The lack of vaccines and disease-specific therapeutics for Bundibugyo Ebola has dramatically affected the community’s perception of Ebola treatment centers. In this context, trust becomes critical.
- Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026 August 6, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

I would titrate to effect. After all, we use fentanyl patches in patients on efavirenz. You just start at a lower dose.
Paul, I would sedate as usual as it has been my experience (hundreds of cases of endoscopy in patients on these meds) that there are no significant adverse effects, and there are no cases of clinically relevant drug interactions using fentanyl/midazolam for conscious sedation in patients on these agents (thousands of cases). Until it is a clinical relevant interaction (vs pharmacological or theoretical effect as it is at this time), deviating from a safe and time-tested sedation strategy for endoscopy does not seem justified.
Brian, many thanks for your input — will share with our colleagues.
Paul
[…] HIV-Infected Endoscopy Patients Posted by M. Brian Fennerty on March 14th, 2009 In a recent blog post, ID expert Paul Sax raised the question of which sedatives should be used when scoping HIV-infected […]